PORTRAZZA
(Necitumumab)Phase 2Monoclonal antibody
Eli LillyPORTRAZZA is a monoclonal antibody that works as a Epidermal Growth Factor Receptor Erbb1 Inhibitor.[2] It is being investigated across 7 indications, with its most advanced program in Phase 2.[1]
PORTRAZZA is one of 134 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
7
Indications
18
Total Trials
3
Active Trials
133
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1PORTRAZZA
Eli LillyPhase 2
Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Lenvima
EisaiPreclinical
Imjudo
AstraZenecaPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer8 trials
Show 5 more trials
Lung Cancer4 trials
Nab-paclitaxel1 trial
Squamous Cell Carcinoma1 trial
3 more indications
Interaction1 trial
Pembrolizumab1 trial
Regulatory
FDA Approval Timeline[4]
Nov 24, 2015
PORTRAZZA
BLA BLA125547
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Necitumumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]